<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02606799</url>
  </required_header>
  <id_info>
    <org_study_id>KIM_CS_001</org_study_id>
    <nct_id>NCT02606799</nct_id>
  </id_info>
  <brief_title>Extracorporeal Elimination of Cytokines Following Abdominal-thoracic Esophagectomy</brief_title>
  <acronym>EXCESS</acronym>
  <official_title>Extracorporeal Elimination of Cytokines Following Abdominal-thoracic Esophagectomy - a Randomized Study (EXCESS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CytoSorbents, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of extracorporeal removal of inflammatory mediators on the
      systemic inflammation reaction of patients admitted to the intensive care unit following
      elective esophagectomy. Half of the participants will be treated with an adsorption device
      (CytoSorbents Adsorber), while the other half will be treated according to standard care.
      Significant reductions of interleukin-6 plasma concentration, SOFA score and catecholamine
      dosage in the intervention group are expected.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radical esophagectomy combined with extensive lymphadenectomy for esophageal cancer is one of
      the most invasive surgical procedures. Even with progress made in surgical technique and
      postoperative management the rate of short- and long term complications remains high. The
      surgical trauma invariably causes liberation and activation of inflammatory mediators and
      danger associated molecular patterns, which in turn result in a pronounced systemic
      inflammatory reaction, leading to multiorgan dysfunction including adult respiratory distress
      syndrome (ARDS) in many patients. The subsequent counter regulation of the immune system
      induces immune paralysis, which is followed by infectious complications and increases the
      probability of severe sepsis. Moreover, severe systemic inflammation causes capillary
      leakage, resulting in impaired wound healing and endangered anastomoses.

      Therefore, it seems that early and effective measures against the excessive production of
      mediators and cytokines are indicated without impairment of the innate and adaptive immune
      response as it would be expected with the administration of e.g. steroids. Instead, the
      removal of an excessive amount of circulating cytokines might be a desirable method having
      shown its effectivity in the therapy of septic shock in the past.

      The aim of this study is to demonstrate the effectiveness of extracorporeal cytokine removal
      to dampen the systemic inflammatory response following abdominal-thoracic esophagectomy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of interleukin-6 plasma levels</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in SOFA Score</measure>
    <time_frame>120 hours</time_frame>
    <description>decrease of &gt;= 2 score points in the intervention group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of catecholamine dose</measure>
    <time_frame>48 hours</time_frame>
    <description>decrease of &gt;= 0.1 µg/kg/min catecholamine dosage to achieve MAP &gt; 65 mmHg in intervention group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid intake</measure>
    <time_frame>120 hours</time_frame>
    <description>reduction of fluid intake to maintain MAP &gt; 65 mmHg of &gt;= 1000 ml/24h in intervention group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>intensive care therapy according to international standards and following local SOPs, including fluid therapy, mechanical ventilation, catecholamine therapy and other pharmacotherapy as required</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CytoSorb</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>all of the above, plus extracorporeal hemadsorption therapy (CytoSorbents Adsorber cartridge) using continuous veno-venous hemofiltration (citrate anticoagulation) CytoSorb cytokine elimination</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CytoSorb cytokine elimination</intervention_name>
    <description>Hemoperfusion using continuous veno-venous hemofiltration (citrate regional anticoagulation) with CytoSorb cytokine elimination over a period of 48h immediately following admission to the intensive care unit</description>
    <arm_group_label>CytoSorb</arm_group_label>
    <other_name>hemadsorption</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  abdominal-thoracic esophagectomy with radical lymphadenectomy

          -  post operative admission to ICU

          -  age &gt;= 18 yrs

          -  written informed consent

        Exclusion Criteria:

          -  Participation in another interventional trial

          -  pregnancy or lactation

          -  systemic medication with high dose steroids and/or immunosuppressants and/or
             radiotherapy during the last 3 months

          -  known diseases of the immune system (benign and malign)

          -  contraindications for extracorporeal therapy

          -  Thrombocytopenia &lt; 50*10^9/l

          -  therapy limitations (DNR), moribund status

          -  missing informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Axel Nierhaus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Hamburg-Eppendorf, Dep. of Critical Care</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Kluge, MD</last_name>
    <phone>+49 40 7410 57010</phone>
    <email>s.kluge@uke.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Axel Nierhaus, MD</last_name>
    <phone>+49 40 7410 55325</phone>
    <email>nierhaus@uke.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Kluge, MD</last_name>
      <phone>+49 40 7410 57010</phone>
      <email>s.kluge@uke.de</email>
    </contact>
    <contact_backup>
      <last_name>Axel Nierhaus, MD</last_name>
      <phone>+49 40 7410 55325</phone>
      <email>nierhaus@uke.de</email>
    </contact_backup>
    <investigator>
      <last_name>Axel Nierhaus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://cytosorb-therapy.com/</url>
    <description>technical and scientific information</description>
  </link>
  <reference>
    <citation>Panagiotou A, Gaiao S, Cruz DN. Extracorporeal therapies in sepsis. J Intensive Care Med. 2013 Sep-Oct;28(5):281-95. doi: 10.1177/0885066611425759. Epub 2011 Oct 25. Review.</citation>
    <PMID>22027760</PMID>
  </reference>
  <reference>
    <citation>Bruenger F, Kizner L, Weile J, Morshuis M, Gummert JF. First successful combination of ECMO with cytokine removal therapy in cardiogenic septic shock: a case report. Int J Artif Organs. 2015 Feb;38(2):113-6. doi: 10.5301/ijao.5000382. Epub 2015 Feb 3.</citation>
    <PMID>25656010</PMID>
  </reference>
  <reference>
    <citation>Kellum JA, Song M, Venkataraman R. Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-kappaB DNA binding, and improves short-term survival in lethal endotoxemia. Crit Care Med. 2004 Mar;32(3):801-5.</citation>
    <PMID>15090965</PMID>
  </reference>
  <reference>
    <citation>Basu R, Pathak S, Goyal J, Chaudhry R, Goel RB, Barwal A. Use of a novel hemoadsorption device for cytokine removal as adjuvant therapy in a patient with septic shock with multi-organ dysfunction: A case study. Indian J Crit Care Med. 2014 Dec;18(12):822-4. doi: 10.4103/0972-5229.146321.</citation>
    <PMID>25538418</PMID>
  </reference>
  <reference>
    <citation>Mitzner SR, Gloger M, Henschel J, Koball S. Improvement of hemodynamic and inflammatory parameters by combined hemoadsorption and hemodiafiltration in septic shock: a case report. Blood Purif. 2013;35(4):314-5. doi: 10.1159/000351206. Epub 2013 Jul 31.</citation>
    <PMID>23920222</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2015</study_first_submitted>
  <study_first_submitted_qc>November 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2015</study_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Esophagectomy Inflammation Hemoperfusion Cytokines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

